Upgrade to SI Premium - Free Trial

Cytokinetics (CYTK) PT Raised to $119 at RBC Capital

May 6, 2026 4:19 AM
RBC Capital analyst Leonid Timashev raised the price target on Cytokinetics (NASDAQ: CYTK) to $119.00 (from $101.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change